{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:00:27Z","timestamp":1789884027607,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T00:00:00Z","timestamp":1424217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Scalp and nail psoriasis have a major impact on quality of life and are traditionally resistant to therapy. Ixekizumab is a monoclonal antibody that targets <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A, a key cytokine in psoriasis pathogenesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Changes in nail and scalp psoriasis associated with ixekizumab treatment were evaluated in a post hoc analysis of a phase 2 study comprising a 20\u2010week randomized, placebo\u2010controlled (<jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>) period and 48\u00a0weeks of an open\u2010label extension (<jats:styled-content style=\"fixed-case\">OLE<\/jats:styled-content>) period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>There were 142 patients with moderate\u2010to\u2010severe plaque psoriasis at baseline of the <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>. Patients were randomized to receive placebo, 10, 25, 75 or 150\u00a0mg of ixekizumab injected subcutaneously at weeks 0, 2, 4, 8, 12 and 16. In the <jats:styled-content style=\"fixed-case\">OLE<\/jats:styled-content>, all patients received 120\u00a0mg ixekizumab every 4\u00a0weeks. Nail Psoriasis Severity Index (<jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content>) and Psoriasis Scalp Severity Index (<jats:styled-content style=\"fixed-case\">PSSI<\/jats:styled-content>) were used to evaluate nail and scalp psoriasis respectively. Fifty\u2010eight (41.0%) patients had nail psoriasis (<jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content>\u00a0&gt;\u00a00) and 105 (74.0%) had scalp psoriasis (<jats:styled-content style=\"fixed-case\">PSSI<\/jats:styled-content>\u00a0&gt;\u00a00) at baseline; these cases were evaluated for the present analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content> week 20, patients with scalp psoriasis in the 25\u2010, 75\u2010 and 150\u2010mg groups had significant mean change and percent improvement from baseline <jats:styled-content style=\"fixed-case\">PSSI<\/jats:styled-content> of \u221216.3 (75.3%; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.001), \u221211.6 (83.7%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001) and \u221218.2 (82.2%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) respectively compared to \u22126.0 (18.8%) in placebo. Patients with nail psoriasis in the 75\u2010 and 150\u2010mg groups had significant improvements from baseline <jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content> of \u221226.3 (63.8%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.003) and \u221223.1 (52.6%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.009) respectively compared to 0.4 (\u22121.7%) in placebo. By <jats:styled-content style=\"fixed-case\">OLE<\/jats:styled-content> week 48, 78.0% of patients with scalp psoriasis and 51.0% of patients with nail psoriasis experienced complete resolution of lesions (<jats:styled-content style=\"fixed-case\">PSSI<\/jats:styled-content>\u00a0=\u00a00 or <jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content>\u00a0=\u00a00).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ixekizumab monotherapy improved scalp psoriasis quickly with maintenance of clinical response and complete resolution of plaques in the majority of patients. Additionally, over 50.0% of patients with nail psoriasis experienced complete resolution of nail lesions by <jats:styled-content style=\"fixed-case\">OLE<\/jats:styled-content> week 48.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12996","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T02:17:06Z","timestamp":1424312226000},"page":"1763-1770","source":"Crossref","is-referenced-by-count":69,"title":["Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis"],"prefix":"10.1111","volume":"29","author":[{"given":"R.G.","family":"Langley","sequence":"first","affiliation":[{"name":"Division of Clinical Dermatology and Cutaneous Science Department of Medicine Dalhousie University Halifax NS Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rich","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oregon Health &amp; Science University School of Medicine Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Menter","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Texas Southwestern Medical Center Southwestern Medical School Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Utah School of Medicine Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Goldblum","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Dutronc","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wei","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.","family":"Cameron","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Heffernan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.022"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12368"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102030-00005"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12173_suppl"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09831.x"},{"key":"e_1_2_7_7_1","first-page":"1","article-title":"Nail psoriasis as a severity indicator: results from the PsoReal study","volume":"2","author":"Radtke MA","year":"2011","journal-title":"Patient Relat Outcome Meas"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246274"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.10.026"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000018026"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03938.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02424.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12054_suppl"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.034"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-5174.2009.00023.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.851192"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12359"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1610-0387.2010.07412.x","article-title":"Scalp psoriasis","volume":"9","author":"Wozel G","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03211.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12060"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000317775"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08686.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12553"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.042"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12632"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03426.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12996","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:12:51Z","timestamp":1695492771000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,18]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/jdv.12996"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12996","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,18]]}}}